PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Adfactors PR (P) Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IBS Signs MoU with Government of Gujarat – Partners with Gujarat State Biotechnology Mission - IBS Centre for Bioinformatics to offer state-of-the-art research-based Biotechnology solutions towards modern medicine and therapy research
IBS Signs MoU with Government of Gujarat – Partners with Gujarat State Biotechnology Mission

 

NewswireToday - /newswire/ - Mumbai, Maharashtra, India, 2007/01/15 - IBS Centre for Bioinformatics to offer state-of-the-art research-based Biotechnology solutions towards modern medicine and therapy research.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Intelligent Business Systems (IBS) and Government of Gujarat have signed a Memorandum of Understanding (MoU) today to partner in Gujarat State Biotechnology Mission. Gujarat is the first state in India to set up a Biotechnology Solutions Venture which will be aimed at Research Outsourcing. As part of the MoU, Intelligent Business Systems Centre for Bioinformatics (CfB) along with Shanku’s Group will be providing the Bioinformatics & Biotechnology research based solutions respectively.

IBS will deal with computer-aided drug discovery, drug interaction and bio-analysis. Also, Shanku’s group will be investing Rs. 40 crore for the venture.

Speaking on the occasion, Dr. Kaustubh Chokshi, CEO and co-Founder, IBS, said, “Gujarat with its very strong Pharma, Healthcare and Agriculture sectors offers an ideal platform to venture into the emerging Biotechnology industry. IBS with its strong academic roots and research based approach to providing innovative solutions, is privileged to be part of this initiative to tap the growing opportunity that Biotechnology offers.”

He added, “At IBS we pioneer the use of novel and developmental bioinformatics research. IBS (intelligentsystems.biz) will offer cutting edge solutions to facilitate the goals of modern medicine and therapy research.”

Intelligent Business Systems’ CfB specialises in research and data analysis, which can be extended to provide an invaluable analytical insight into biological data and utilities to aid the scientific and commercial community in the understanding of genomic and proteomic data.

CfB will collaborate with academia on problems of relevance to improve medication and healthcare delivery. The mathematical approach has numerous cutting-edge applications in modern medicine and therapy development.
These include:

• Individuals responding adversely to one or more drugs;
• Predicting disease and treatment outcomes;
• Improved economic and practical efficiencies in healthcare delivery, thus better targeting high cost treatment to those patients most likely to benefit from it;
• Computationally complete genome sequence analysis and comparative genomics;
• Development of intelligent systems for genome;
• Protein interaction maps using gene fusion events;
• Pattern discovery;
• Evolution of the transcriptional machinery;
• Development of standards for genome sequence annotation;
• Document clustering and information extraction from biological text;
• Precocious diagnosis of life-threatening disease.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Adfactors PR (P) Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IBS Signs MoU with Government of Gujarat – Partners with Gujarat State Biotechnology Mission

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Aniket Thakur - AdfactorsPR.com 
+91 98 92173022 aniket.thakur[.]adfactorspr.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Adfactors PR (P) Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Adfactors PR (P) Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)